Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Animals
Antibodies, Monoclonal, Murine-Derived
Cyclin D1
Cyclophosphamide
Daunorubicin
Disease-Free Survival
Female
Humans
Immunohistochemistry
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Mantle-Cell
Male
Mice
Middle Aged
Prednisone
Prevalence
Prognosis
Rituximab
Vincristine
Young Adult

authors with profiles

L JEFFREY MEDEIROS
KEN HE YOUNG
CHI YOUNG OK
ZIJUN XU-MONETTE